EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BCAM-AKT2 fusion protein promotes unfolded protein response driven oncogenic signaling in SKOV3 epithelial ovarian cancer cell line

Hala Khazem, Ravid Solomon Zemler iD, Liron Vardi David iD, Dvir Reder, Shilhav Meisel Sharon, Shay Hantisteanu, Haim Werner, Ilan Bruchim iD

PLOS One · 2026

DOI: 10.1371/journal.pone.0357882 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Hala Khazem und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gynecologic Oncology Laboratory, Division of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Unfolded Protein Response, Signal Transduction, Ovarian Neoplasms. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In view of the rapidly increasing evidence that gene fusion mutations are frequent drivers of cancer, a deeper understanding of the molecular and functional hallmarks of specific gene fusions in epithelial ovarian cancer (EOC) is essential. In this work we sought to identify the molecular signature of the BCAM-AKT2 fusion protein in ovarian cancer cell lines and to assess the biological impact of the novel fusion in these cells. Our in-vitro results show that the BCAM-AKT2 fusion protein is engaged in proliferative action within EOC cell lines. Furthermore, RNA-seq analysis shows that the effect of BCAM-AKT2 in SKOV3 cells is associated with activated unfolded protein response (UPR) and with the inhibition of interferon alpha and beta signaling pathways, pyropstosis and viral response in EOC cell lines. Overall, our results indicate that in SKOV3 cells, BCAM-AKT2 modulates the UPR signaling pathway, which is known to interact with oncogene and tumor suppressor networks during cancer development. These findings offer fresh insights suggesting that BCAM-AKT2 could serve as a promising target for therapeutic interventions in ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-aktUnfolded Protein ResponseSignal TransductionOvarian NeoplasmsCarcinoma, Ovarian EpithelialOncogene Proteins, FusionHumansFemaleCell Line, TumorCell ProliferationGene Expression Regulation, Neoplastic

Substanzen

Proto-Oncogene Proteins c-aktOncogene Proteins, FusionAKT2 protein, human

Autor:innen und Institutionen

  • Gynecologic Oncology Laboratory, Division of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel.
  • The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
  • Division of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel.
  • Department of Human Molecular Genetics and Biochemistry, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

ORCID-Profile: Ravid Solomon Zemler, Liron Vardi David, Ilan Bruchim

Zitieren

APA

Khazem, H., Zemler, R. S., David, L. V., Reder, D., Sharon, S. M., Hantisteanu, S., Werner, H., & Bruchim, I. (2026). BCAM-AKT2 fusion protein promotes unfolded protein response driven oncogenic signaling in SKOV3 epithelial ovarian cancer cell line. PLOS One. https://doi.org/10.1371/journal.pone.0357882

Vancouver

Khazem H, Zemler RS, David LV, Reder D, Sharon SM, Hantisteanu S, et al. BCAM-AKT2 fusion protein promotes unfolded protein response driven oncogenic signaling in SKOV3 epithelial ovarian cancer cell line. PLOS One. 2026. doi:10.1371/journal.pone.0357882

BibTeX
@article{Khazem2026,
  author = {Khazem, Hala and Zemler, Ravid Solomon and David, Liron Vardi and Reder, Dvir and Sharon, Shilhav Meisel and Hantisteanu, Shay and Werner, Haim and Bruchim, Ilan},
  title = {BCAM-AKT2 fusion protein promotes unfolded protein response driven oncogenic signaling in SKOV3 epithelial ovarian cancer cell line},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0357882}
}
Kostenlos starten →